Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Aug 10, 2014; 5(3): 393-405
Published online Aug 10, 2014. doi: 10.5306/wjco.v5.i3.393
Published online Aug 10, 2014. doi: 10.5306/wjco.v5.i3.393
Toremifene in the treatment of breast cancer
Mika VJ Mustonen, Orion Corporation, Orion Pharma, FIN-02101, Espoo, Finland
Seppo Pyrhönen, Department of Oncology and Radiotherapy, Turku University Hospital and University of Turku, FIN-20520, Turku, Finland
Pirkko-Liisa Kellokumpu-Lehtinen, Department of Oncology, University of Tampere, School of Medicine, Tampere University Hospital, FIN-33520, Tampere, Finland
Author contributions: All the authors contributed to the acquisition of data, preparation of the manuscript, reviewing and amending for intellectual content.
Correspondence to: Mika VJ Mustonen, PhD, Orion Corporation, Orion Pharma, Orionintie 1, FIN-02101, Espoo, Finland. mika.mustonen@orionpharma.com
Telephone: +358-50-9664804 Fax: +358-50-9664804
Received: December 18, 2013
Revised: April 8, 2014
Accepted: May 28, 2014
Published online: August 10, 2014
Revised: April 8, 2014
Accepted: May 28, 2014
Published online: August 10, 2014
Core Tip
Core tip: Toremifene is safe and effective in the treatment of breast cancer. Toremifene and tamoxifen are equivalently effective in the treatment of breast cancer, although some studies show an advantage for toremifene. Safety and tolerability is also broadly equivalent, although toremifene may cause fewer uterine neoplasms, serious vascular adverse events and has a more beneficial effect on plasma lipids than does tamoxifen.